JP2003505111A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003505111A5 JP2003505111A5 JP2001513645A JP2001513645A JP2003505111A5 JP 2003505111 A5 JP2003505111 A5 JP 2003505111A5 JP 2001513645 A JP2001513645 A JP 2001513645A JP 2001513645 A JP2001513645 A JP 2001513645A JP 2003505111 A5 JP2003505111 A5 JP 2003505111A5
- Authority
- JP
- Japan
- Prior art keywords
- tenascin
- nucleic acid
- nucleic acids
- candidate mixture
- modified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000007523 nucleic acids Chemical class 0.000 description 64
- 102000039446 nucleic acids Human genes 0.000 description 64
- 108020004707 nucleic acids Proteins 0.000 description 64
- 102000007000 Tenascin Human genes 0.000 description 31
- 108010008125 Tenascin Proteins 0.000 description 31
- 239000003446 ligand Substances 0.000 description 31
- 239000000203 mixture Substances 0.000 description 31
- 238000000034 method Methods 0.000 description 29
- 239000003550 marker Substances 0.000 description 10
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 6
- 229920002477 rna polymer Polymers 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 3
- GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 229940056501 technetium 99m Drugs 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/364,902 US6232071B1 (en) | 1990-06-11 | 1999-07-29 | Tenascin-C nucleic acid ligands |
| US09/364,902 | 1999-07-29 | ||
| PCT/US2000/002167 WO2001009390A1 (en) | 1999-07-29 | 2000-01-28 | Tenascin-c nucleic acid ligands |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003505111A JP2003505111A (ja) | 2003-02-12 |
| JP2003505111A5 true JP2003505111A5 (https=) | 2007-03-01 |
Family
ID=23436596
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001513645A Pending JP2003505111A (ja) | 1999-07-29 | 2000-01-28 | テネイシンｃの核酸リガンド |
Country Status (29)
| Country | Link |
|---|---|
| US (4) | US6232071B1 (https=) |
| EP (1) | EP1198589B9 (https=) |
| JP (1) | JP2003505111A (https=) |
| KR (1) | KR100605072B1 (https=) |
| CN (2) | CN100558411C (https=) |
| AT (1) | ATE405675T1 (https=) |
| AU (1) | AU767501C (https=) |
| BG (1) | BG106361A (https=) |
| BR (1) | BR0013170A (https=) |
| CA (1) | CA2380473A1 (https=) |
| CZ (1) | CZ2002365A3 (https=) |
| DE (1) | DE60039986D1 (https=) |
| DK (1) | DK1198589T3 (https=) |
| EA (1) | EA004795B1 (https=) |
| EE (1) | EE200200051A (https=) |
| ES (1) | ES2310989T3 (https=) |
| HK (1) | HK1048499B (https=) |
| HR (1) | HRP20020186A2 (https=) |
| HU (1) | HUP0202221A3 (https=) |
| IL (2) | IL147872A0 (https=) |
| MX (1) | MXPA02000819A (https=) |
| NO (1) | NO20020424L (https=) |
| NZ (2) | NZ516907A (https=) |
| PL (1) | PL201637B1 (https=) |
| RS (1) | RS50426B (https=) |
| SK (1) | SK1222002A3 (https=) |
| UA (1) | UA75578C2 (https=) |
| WO (1) | WO2001009390A1 (https=) |
| ZA (1) | ZA200200747B (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6232071B1 (en) * | 1990-06-11 | 2001-05-15 | Gilead Sciences, Inc. | Tenascin-C nucleic acid ligands |
| US7005260B1 (en) * | 2000-01-28 | 2006-02-28 | Gilead Sciences, Inc. | Tenascin-C nucleic acid ligands |
| US7645743B2 (en) * | 1999-12-22 | 2010-01-12 | Altermune, Llc | Chemically programmable immunity |
| CA2328356A1 (en) | 1999-12-22 | 2001-06-22 | Itty Atcravi | Recreational vehicles |
| US7300922B2 (en) | 2001-05-25 | 2007-11-27 | Duke University | Modulators of pharmacological agents |
| US20040249130A1 (en) * | 2002-06-18 | 2004-12-09 | Martin Stanton | Aptamer-toxin molecules and methods for using same |
| JP2005533794A (ja) * | 2002-06-18 | 2005-11-10 | アーケミックス コーポレイション | アプタマー−毒素分子およびこれを使用する方法 |
| US8853376B2 (en) | 2002-11-21 | 2014-10-07 | Archemix Llc | Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
| US8039443B2 (en) * | 2002-11-21 | 2011-10-18 | Archemix Corporation | Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
| US10100316B2 (en) | 2002-11-21 | 2018-10-16 | Archemix Llc | Aptamers comprising CPG motifs |
| US7727969B2 (en) * | 2003-06-06 | 2010-06-01 | Massachusetts Institute Of Technology | Controlled release nanoparticle having bound oligonucleotide for targeted delivery |
| US20080268478A1 (en) * | 2005-03-01 | 2008-10-30 | Cedars-Sinai Medical Center | Use of Eotaxin as a Diagnostic Indicator For Atherosclerosis and Vascular Inflammation |
| AR052741A1 (es) * | 2005-04-08 | 2007-03-28 | Noxxon Pharma Ag | Acidos nucleicos de union a ghrelin |
| JP5603074B2 (ja) | 2006-09-08 | 2014-10-08 | ピラマル イメージング ソシエテ アノニム | １８ｆ標識物質のための化合物と方法 |
| EP1897562A1 (en) * | 2006-09-08 | 2008-03-12 | Bayer Schering Pharma Aktiengesellschaft | Aptamers labelled with Gallium-68 |
| US20110136099A1 (en) | 2007-01-16 | 2011-06-09 | Somalogic, Inc. | Multiplexed Analyses of Test Samples |
| US8975026B2 (en) | 2007-01-16 | 2015-03-10 | Somalogic, Inc. | Method for generating aptamers with improved off-rates |
| DK2172566T4 (da) * | 2007-07-17 | 2022-06-13 | Somalogic Inc | Fremgangsmåde til generering af aptamerer med forbedrede off-rates |
| EP2036981A1 (en) * | 2007-09-12 | 2009-03-18 | Bayer Schering Pharma Aktiengesellschaft | Aptamers labeled with 18F |
| BRPI1011269A2 (pt) | 2009-05-05 | 2016-09-27 | Altermune Technologies Llc | imunidade quimicamente programável |
| US8841429B2 (en) | 2009-11-03 | 2014-09-23 | Vivonics, Inc. | Nucleic acid ligands against infectious prions |
| US8236570B2 (en) | 2009-11-03 | 2012-08-07 | Infoscitex | Methods for identifying nucleic acid ligands |
| GB201114662D0 (en) | 2011-08-24 | 2011-10-12 | Altermune Technologies Llc | Chemically programmable immunity |
| WO2013088140A2 (en) * | 2011-12-12 | 2013-06-20 | Isis Innovation Limited | Biomarker and use thereof |
| CN102533772B (zh) * | 2011-12-12 | 2013-10-09 | 中国科学院武汉病毒研究所 | 一种抗hbv诱饵适体及其筛选方法 |
| JP6453212B2 (ja) | 2012-07-13 | 2019-01-16 | ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． | キラル制御 |
| CN107058596A (zh) * | 2017-06-19 | 2017-08-18 | 上海市第十人民医院 | 一种与恶性胶质瘤诊断相关的标志物及其应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2183661B (en) | 1985-03-30 | 1989-06-28 | Marc Ballivet | Method for obtaining dna, rna, peptides, polypeptides or proteins by means of a dna recombinant technique |
| WO1989006694A1 (en) | 1988-01-15 | 1989-07-27 | Trustees Of The University Of Pennsylvania | Process for selection of proteinaceous substances which mimic growth-inducing molecules |
| US5789157A (en) * | 1990-06-11 | 1998-08-04 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: tissue selex |
| US5496938A (en) * | 1990-06-11 | 1996-03-05 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligands to HIV-RT and HIV-1 rev |
| US6610841B1 (en) * | 1997-12-18 | 2003-08-26 | Gilead Sciences, Inc. | Nucleotide-based prodrugs |
| US6127119A (en) * | 1990-06-11 | 2000-10-03 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligands of tissue target |
| US6232071B1 (en) * | 1990-06-11 | 2001-05-15 | Gilead Sciences, Inc. | Tenascin-C nucleic acid ligands |
| EP0786469B1 (en) * | 1990-06-11 | 2006-03-01 | Gilead Sciences, Inc. | Methods of use of nucleic acid ligands |
| CA2104698A1 (en) | 1991-02-21 | 1992-08-22 | John J. Toole | Aptamers specific for biomolecules and methods of making |
| US5683874A (en) * | 1991-03-27 | 1997-11-04 | Research Corporation Technologies, Inc. | Single-stranded circular oligonucleotides capable of forming a triplex with a target sequence |
| US5582981A (en) * | 1991-08-14 | 1996-12-10 | Gilead Sciences, Inc. | Method for identifying an oligonucleotide aptamer specific for a target |
| US5436132A (en) * | 1993-02-13 | 1995-07-25 | Amano Pharmaceutical Co., Ltd. | Quantitative determination of tenascin as glioma marker |
| US5859228A (en) * | 1995-05-04 | 1999-01-12 | Nexstar Pharmaceuticals, Inc. | Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes |
| US6229002B1 (en) * | 1995-06-07 | 2001-05-08 | Nexstar Pharmaceuticlas, Inc. | Platelet derived growth factor (PDGF) nucleic acid ligand complexes |
| DE69735292T2 (de) * | 1996-10-25 | 2006-10-19 | Gilead Sciences, Inc., Foster City | Gefaesszellen wachstumsfaktor (vegf) nukleinsäureligand-komplexe |
| US6242246B1 (en) * | 1997-12-15 | 2001-06-05 | Somalogic, Inc. | Nucleic acid ligand diagnostic Biochip |
-
1999
- 1999-07-29 US US09/364,902 patent/US6232071B1/en not_active Expired - Fee Related
-
2000
- 2000-01-28 PL PL353357A patent/PL201637B1/pl not_active IP Right Cessation
- 2000-01-28 EP EP00911657A patent/EP1198589B9/en not_active Expired - Lifetime
- 2000-01-28 HU HU0202221A patent/HUP0202221A3/hu unknown
- 2000-01-28 SK SK122-2002A patent/SK1222002A3/sk not_active Application Discontinuation
- 2000-01-28 KR KR1020027001167A patent/KR100605072B1/ko not_active Expired - Fee Related
- 2000-01-28 WO PCT/US2000/002167 patent/WO2001009390A1/en not_active Ceased
- 2000-01-28 UA UA2002021549A patent/UA75578C2/uk unknown
- 2000-01-28 ES ES00911657T patent/ES2310989T3/es not_active Expired - Lifetime
- 2000-01-28 HR HR20020186A patent/HRP20020186A2/hr not_active Application Discontinuation
- 2000-01-28 MX MXPA02000819A patent/MXPA02000819A/es not_active IP Right Cessation
- 2000-01-28 BR BR0013170-9A patent/BR0013170A/pt not_active Application Discontinuation
- 2000-01-28 HK HK03100657.1A patent/HK1048499B/zh not_active IP Right Cessation
- 2000-01-28 NZ NZ516907A patent/NZ516907A/en unknown
- 2000-01-28 EA EA200200094A patent/EA004795B1/ru not_active IP Right Cessation
- 2000-01-28 CN CNB2004100629077A patent/CN100558411C/zh not_active Expired - Fee Related
- 2000-01-28 AT AT00911657T patent/ATE405675T1/de not_active IP Right Cessation
- 2000-01-28 EE EEP200200051A patent/EE200200051A/xx unknown
- 2000-01-28 CA CA002380473A patent/CA2380473A1/en not_active Abandoned
- 2000-01-28 IL IL14787200A patent/IL147872A0/xx active IP Right Grant
- 2000-01-28 DK DK00911657T patent/DK1198589T3/da active
- 2000-01-28 AU AU33519/00A patent/AU767501C/en not_active Ceased
- 2000-01-28 DE DE60039986T patent/DE60039986D1/de not_active Expired - Lifetime
- 2000-01-28 CZ CZ2002365A patent/CZ2002365A3/cs unknown
- 2000-01-28 JP JP2001513645A patent/JP2003505111A/ja active Pending
- 2000-01-28 CN CNB008109796A patent/CN1164760C/zh not_active Expired - Fee Related
- 2000-01-28 RS YUP-64/02A patent/RS50426B/sr unknown
- 2000-01-29 NZ NZ528077A patent/NZ528077A/en unknown
-
2001
- 2001-05-14 US US09/854,662 patent/US6596491B2/en not_active Expired - Fee Related
-
2002
- 2002-01-28 ZA ZA200200747A patent/ZA200200747B/xx unknown
- 2002-01-28 IL IL147872A patent/IL147872A/en not_active IP Right Cessation
- 2002-01-28 NO NO20020424A patent/NO20020424L/no not_active Application Discontinuation
- 2002-01-29 BG BG106361A patent/BG106361A/bg unknown
-
2003
- 2003-05-01 US US10/429,176 patent/US20040058884A1/en not_active Abandoned
-
2005
- 2005-12-13 US US11/300,662 patent/US20060105378A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003505111A5 (https=) | ||
| AU767501C (en) | Tenascin-C nucleic acid ligands | |
| US6013443A (en) | Systematic evolution of ligands by exponential enrichment: tissue SELEX | |
| AU1600499A (en) | Nucleic acid ligands of tissue target | |
| JP2004511250A (ja) | 前立腺特異的膜抗原に対する核酸リガンド | |
| JP2009197024A (ja) | 金属複合体及びオリゴヌクレオチドから作られた接合体、該接合体を含む薬剤、放射線診断におけるそれらの使用並びにそれらの製造のための方法 | |
| TW200812626A (en) | Aptamers labeled with 68GA | |
| WO2020020947A1 (en) | Icam-1 aptamers, diagnostic and therapeutic uses thereof | |
| JP7671279B2 (ja) | Ｃａ－ｉｘアプタマー並びにその診断的および治療的使用 | |
| US7005260B1 (en) | Tenascin-C nucleic acid ligands | |
| WO1996040273A2 (en) | Conjugates of ferrites and oligonucleotides, which bond specifically to certain target structures | |
| CN118477186A (zh) | 一种靶向s2亚基的正电子发射断层显像评价治疗变异新冠病毒感染的方法 | |
| JP2004503214A5 (https=) | ||
| CN112920248A (zh) | 放射性核素99mTc标记的LncRNA HOTAIR靶向探针、制备方法以及显像剂 |